ALIM - Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

• Alimera Sciences ( NASDAQ: ALIM ) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Portugal.
• ALIM said the reimbursement was granted by Portugal's National Authority of Medicines and Health Products with no change to the current label.
• The reimbursement decision by Portugal follows similar approvals for Iluvien in France and Italy in July.
• “This summer has been a productive one for expanding availability of our non-infectious uveitis indication in our International Segment with it soon to be accessible to patients in all of our direct markets in addition to our key distributor markets,” ALIM CEO Rick Eiswirth said in a statement .
• ALIM said it is planning to launch Iluvien in Portugal and France in Q3.
• Alimera ( ALIM ) stock closed +2.6% at $7.18 on Monday.

For further details see: